Evidence map›Paper›PMID 33672296›Full record

ArticleCells2021

A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts.

Tianxia Li, Bo Ning, Lingbo Kong, Bingling Dai, Xiaofei He, Joseph M Thomas, Akira Sawa, Christopher A Ross, Wanli W Smith

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Leucine-rich repeat kinase 2 at a glance.Journal of cell science · 2023
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Exploring the focal role of LRRK2 kinase in Parkinson's disease.Environmental science and pollution research international · 2022
    Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Tianxia LiDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Bo NingDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Lingbo KongDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Bingling DaiDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Xiaofei HeDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Joseph M ThomasDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA.
Akira SawaDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Christopher A RossDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Wanli W SmithDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-6482-5154
Johns Hopkins University · USUniversity of Maryland, Baltimore · US

Funding

Project 3P50MH094268 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SAWA, AKIRA · 2011 to 2020
$19.9M
Advanced MRI Studies of Cerebrovascular and Lymphatic Abnormalities in LRRK2 mouse models of Parkinson's diseaseR01NS120879 · NINDS · JOHNS HOPKINS UNIVERSITY · PI HUA, JUN, SMITH, WANLI W · 2021 to 2025
$3.5M
LRRK2, KIF5A and Parkinson diseaseR01NS093383 · NINDS · JOHNS HOPKINS UNIVERSITY · PI SMITH, WANLI W · 2016 to 2020
$2.1M
LRRK2 dimerization and therapeutic evaluationR21NS096620 · NINDS · JOHNS HOPKINS UNIVERSITY · PI SMITH, WANLI W · 2016 to 2017
$455k
NIMH NIH HHS P50 MH094268NINDS NIH HHS R01 NS093383NINDS NIH HHS R01 NS120879NINDS NIH HHS R21 NS096620
6 · The paper itself

Abstract

Mutations in

Indexed as

Signal TransductionEnzyme ActivationGuanosine TriphosphateHEK293 CellsHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LipopolysaccharidesLymphocytesMAP Kinase Signaling SystemModels, BiologicalNF-KappaB Inhibitor alphaPhosphorylationProtein BindingTNF Receptor-Associated Factor 6Tumor Necrosis Factor-alphaGuanosine TriphosphateLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LipopolysaccharidesNF-KappaB Inhibitor alphaTNF Receptor-Associated Factor 6Tumor Necrosis Factor-alphaGTP binding inhibitorLPSLRRK2lymphoblastParkinson’s diseaseTNF-α

Identifiers

PMID33672296
PMCPMC7926966
OpenAlexW3131147115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.